

ISO 10993-1:2018 (E)

Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process

Contents

| | |
|----------|---|
| | Foreword |
| | Introduction |
| 1 | Scope |
| 2 | Normative references |
| 3 | Terms and definitions |
| 4 | General principles applying to biological evaluation of medical devices |
| 5 | Categorization of medical devices |
| 5.1 | General |
| 5.2 | Categorization by nature of body contact |
| 5.2.1 | Non-contacting medical devices |
| 5.2.2 | Surface-contacting medical devices |
| 5.2.3 | Externally communicating medical devices |
| 5.2.4 | Implant medical devices |
| 5.3 | Categorization by duration of contact |
| 5.3.1 | Contact duration categories |
| 5.3.2 | Transitory-contacting medical devices |
| 5.3.3 | Medical devices with multiple contact duration categories |
| 6 | Biological evaluation process |
| 6.1 | Physical and chemical information for biological risk analysis |
| 6.2 | Gap analysis and selection of biological endpoints for assessment |
| 6.3 | Biological testing |
| 6.3.1 | General |
| 6.3.2 | Testing for evaluation |
| 6.3.2.1 | Cytotoxicity |
| 6.3.2.2 | Sensitization |
| 6.3.2.3 | Irritation (including intracutaneous reactivity) |
| 6.3.2.4 | Haemocompatibility |
| 6.3.2.5 | Material-mediated pyrogenicity |
| 6.3.2.6 | Acute systemic toxicity |
| 6.3.2.7 | Subacute and subchronic toxicity |
| 6.3.2.8 | Chronic toxicity |
| 6.3.2.9 | Implantation effects |
| 6.3.2.10 | Genotoxicity |
| 6.3.2.11 | Carcinogenicity |
| 6.3.2.12 | Reproductive and developmental toxicity |
| 6.3.2.13 | Degradation |
| 6.3.2.14 | Toxicokinetic studies |
| 6.3.2.15 | Immunotoxicology |
| 7 | Interpretation of biological evaluation data and overall biological risk assessment |
| Annex A | (informative) Endpoints to be addressed in a biological risk assessment |
| A.1 | General |
| A.2 | Rationale for endpoints in Table A.1 |

Annex B (informative) Guidance on the conduct of biological evaluation within a risk management process

- B.1 Background information**
- B.1.1 General**
- B.1.2 Relationship with other standards, guidance documents and regulatory requirements**
- B.2 Biological evaluation as a risk management practice**
- B.2.1 General**
- B.2.2 The biological evaluation plan**
- B.3 Guidance on risk management**
- B.3.1 Risk assessment**
- B.3.1.1 Introduction**
- B.3.1.2 Risk analysis**
- B.3.1.3 Risk estimation**
- B.3.1.4 Risk evaluation**
- B.3.2 Risk control**
- B.3.3 Evaluation of residual risk acceptability**
- B.3.4 Post production monitoring**
- B.4 Guidance on specific aspects of biological evaluation**
- B.4.1 Material characterization**
- B.4.1.1 Chemical characterization**
- B.4.1.2 Use of chemical characterization data in a biological evaluation**
- B.4.1.3 Proprietary materials formulations**
- B.4.1.4 Physical Characterization**
- B.4.1.5 Effects of manufacturing processes**
- B.4.2 Collection of existing data**
- B.4.3 Device testing considerations**
- B.4.3.1 Tiered approaches to biological testing**
- B.4.3.2 When to do long-term testing (chronic toxicity, reproductive toxicity, degradation and carcinogenicity studies)**
- B.4.3.3 In vitro system pH and osmolality compensation for absorbable materials**
- B.4.4 Biological safety assessment**
- B.4.4.1 Use of clinically relevant data for a risk assessment**
- B.4.4.2 What constitutes “sufficient toxicology data” including dose and route relevance**
- B.4.4.3 Determining the acceptability of the level of leachable (allowable limit) according to ISO 10993-17**
- B.4.4.4 Thresholds of Toxicological Concern (TTC)**
- B.4.4.5 Guidance on mixtures in risk assessment**
- B.4.5 General guidance**
- B.4.5.1 Changes which can require re-evaluation of biological safety**
- B.4.5.2 Good laboratory practice**
- B.4.5.3 Biocompatibility evaluation documentation**

Annex C (informative) Suggested procedure for literature review

- C.1 Introduction**
- C.2 Methodology**
- C.2.1 General**
- C.2.2 Objective(s)**
- C.2.3 Selection criteria for documents**
- C.2.4 Assessment of documents**
- C.2.5 Critical evaluation of the literature**

Page count: 41